Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 18, 2016

Primary Completion Date

August 1, 2017

Study Completion Date

September 1, 2017

Conditions
Overactive Bladder
Interventions
DRUG

Uritos®

film-coated tablets 0.1 mg

DRUG

Urotol®

film coated tablets, 2 mg

Trial Locations (11)

Unknown

Family polyclinic №4, LLC, Korolyov

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Municipal Clinical Hospital named after Spasokukotskiy S.I, Moscow

N.I. Pirogov Russian National Research University, Moscow

National Medical Radiological Center, Moscow

National N.I. Pirogov Medical and Surgical Center, Moscow

Rostov State Medical University, Rostov-on-Don

All-Russian A.M. Nikiforov Center for Emergency and Radiation Medicine, Saint Petersburg

Baltic Medicine LLC, Saint Petersburg

I.P. Pavlov First St. Petersburg State Medical University, Saint Petersburg

OrKli Hospital, LLC, Saint Petersburg

St. Petersburg State-Funded Healthcare Institution St. Luka Clinical Hospital, Saint Petersburg

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Synergy Research Inc.

INDUSTRY

lead

R-Pharm

INDUSTRY

NCT03575702 - Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. | Biotech Hunter | Biotech Hunter